Why is Moderna suing Pfizer and BioNTech over its COVID-19 vaccine despite recent pledge?

This Commentary article explores the applications of mRNA therapeutics in disease treatment and prevention. The commercial presence of microfluidics technologies has improved process development, and has helped to provide rapid development along with the existence of established formulation principles for vaccines.

We interview Vincent Dewar, Associate Director and Head of Immunoassay Analytical Research Development at GlaxoSmithKline, to learn more about the importance of immunoassays for vaccine development.

With influenza expected to make a return this winter, vaccine manufacturers may be facing more demand than usual.

Children between one and nine years old to be given polio jab to curb the spread of the virus throughout the city.

How worrying is the new ‘Langya’ virus spreading in China?

Statistics show that the number of people infected with the monkeypox virus is starting to slow down.

The European Commission (EC) has approved Bavarian Nordic’s Imvanex vaccine which protects against monkeypox, and diseases caused by the vaccinia virus.

Oxford Global’s next round of Biologics Discussion Groups announced.

Exciting updates revealed about upcoming Vaccines Europe: In-Person congress happening 29-30 November 2022.

The US government has more than doubled its supply of Monkeypox vaccines amidst rising fears.

We interview Derek O'Hagan, Senior Advisor at GlaxoSmithKline Vaccines to learn more about the future of the vaccine.